Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade
Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential
Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade
Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential
Credit Suisse Stays Sidelined On Teva: 'Our Growth Expectations Are Below That Of The Company'
Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug
Credit Suisse Stays Sidelined On Teva: 'Our Growth Expectations Are Below That Of The Company'
Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug
Sympathy Move: Portola Upgraded After Competitor Reports Sour Data
Credit Suisse Downgrades AbbVie On Humira Competitive Concerns
Vamil Divan Recent News
Portola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote
Teva's 'Achievable' 2018 Outlook, Restructuring Plan Trigger Credit Suisse Upgrade
Eli Lilly's Challenges Leaves Credit Suisse With A 'Sour Taste'
Credit Suisse Upgrades Teva After Job Cuts Announced
Could The Street Be Underappreciating The Ironwood Pharma Pipeline?
7 Catalysts For Eli Lilly Over The Next Year
Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva
Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'
Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated
Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains
Analyst Prescribes Neutral Rating For Pfizer Shares
Analyst Wonders If AstraZeneca's Soriot Would Be A Fit At Teva
The Street May Be Underappreciating Alder Biopharma's Phase 3 Data
A Surprisingly Clean, Straightforward Approval Gives Portola Pharma Shares A Shot Of Upside
Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse
Portola Announces FDA Drug Application Acceptance, Sets Up For A Pivotal Year Ahead
Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision
Teva Pharmaceuticals Could Be Poised For A Turnaround
AbbVie's Humira Overhang Could Spell Trouble For Co.'s Future Upside
Credit Suisse Changes Its View On Esperion Therapeutics, Raises Price Target
Credit Suisse Can Clearly See Why Johnson & Johnson Acquired Abbott's Optics Division
Pfizer Has Emerged The Victor In The Buyout Battle For Medivation
CheckMate Miss Is A Game Changer; Credit Suisse Downgrades Bristol, Upgrades Merck